Get the Stockscreener App
1.36
28.30%
0.30
After Hours:
1.39
0.03
+2.21%
Pds Biotechnology Corporation stock is traded at $1.36, with a volume of 3.80M.
It is up +28.30% in the last 24 hours and up +115.53% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$1.06
Open:
$1.07
24h Volume:
3.80M
Relative Volume:
5.16
Market Cap:
$75.91M
Revenue:
-
Net Income/Loss:
$-34.50M
P/E Ratio:
-1.8189
EPS:
-0.7477
Net Cash Flow:
$-27.75M
1W Performance:
+37.37%
1M Performance:
+115.53%
6M Performance:
+39.19%
1Y Performance:
+22.52%
1-Day Range:
$1.03
$1.395
1-Week Range:
$0.9507
$1.395
52-Week Range:
$0.5068
$1.915
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.36 | 59.16M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotech Announces Publication of Positive PDS01ADC - GlobeNewswire
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - Traders Union
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday - Defense World
Will PDS Biotechnology Corporation stock go up in YEARPortfolio Profit Report & Safe Entry Momentum Tips - baoquankhu1.vn
Block Trades: Can PDS Biotechnology Corporation stock outperform in a bear market2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
PDSB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology grants 300,000 options to executive | PDSB SEC FilingForm 4 - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
PDS Biotechnology director granted 54,876 options | PDSB SEC FilingForm 4 - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com Australia
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):